- Home
- OTLK vs FOFO Comparison
OTLK vs FOFO Comparison
Compare OTLK & FOFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | FOFO |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | Hong Kong |
| Employees | N/A | 14 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 29.7M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | FOFO |
|---|---|---|
| Price | $0.31 | $3.63 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 51.9K |
| Earning Date | 05-14-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | ★ N/A | $11.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $2.86 |
| 52 Week High | $3.39 | $68.00 |
Technical Indicators
Market Signals| Indicator | OTLK | FOFO |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 43.14 |
| Support Level | $0.17 | $3.78 |
| Resistance Level | $0.46 | $5.74 |
| Average True Range (ATR) | 0.04 | 0.47 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 62.21 | 17.32 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.